At 6 am on September 13, the CSIR handle on X.com published the following post about an "anti-diabetic medicine" called either "Daiba 250" or "Diabe 250", developed at the CSIR-Indian Institute of Integrative Medicine (IIIM):

Its "key features", according to the CSIR, are that it created more than 250 jobs and that Prime Minister Narendra Modi "mentioned the startup" to which it has been licensed in his podcast 'Mann ki Baat'. What of the clinical credentials of Diabe-250, however?

Diabe-250 is being marketed on India-based online pharmacies like Tata 1mg as an "Ayurvedic" over-the-counter tablet "for diabetes support/healthy sugar levels". The listing also claims Diabe-250 is backed by a US patent granted to an Innoveda Biological Solutions Pvt. Ltd. Contrary to the CSIR post calling Diabe-250 "medicine", some listings also carry the disclaimer that it's "a dietary nutritional supplement, not for medicinal use".

("Ayurveda" is within double-quotes throughout this post because, like most products like Diabe-250 in the market that are also licensed by the Ministry of AYUSH, there's no evidence that they're actually Ayurvedic. They may be, they may not be — and until there's credible proof, the Ayurvedic identity is just another claim.)

Second, while e-commerce and brand pages use the spellings "Diabe 250" or "Diabe-250" (without or without the hyphen), the CSIR's social media posts refer to it as "Daiba 250". The latter also describe it as an anti-diabetic developed/produced with the CSIR-IIIM in the context of incubation and licensing. These communications don't constitute clinical evidence but they might be the clearest public basis to link the "Daiba" or "Diabe" spellings with the CSIR.

Multiple product pages also credit Innoveda Biological Solutions Pvt. Ltd. as a marketer and manufacturer. Corporate registry aggregators corroborate the firm's existence; its CIN is U24239DL2008PTC178821). Similarly, the claim that Diabe-250 is backed by a US patent can be traced most directly to US8163312B2 for "Herbal formulation for prevention and treatment of diabetes and associated complications". Its inventor is listed as a G. Geetha Krishnan and Innoveda Biological Solutions (P) Ltd. is listed as the current assignee.

The patent text describes combinations of Indian herbs for diabetes and some complications. Of course no patent is proof of efficacy for any specific branded product or dose.

The ingredients in Diabe-250 vary by retailer and there's no consistent, quantitative per-tablet composition on public pages. This said, multiple listings name the following ingredients:

• "Vidanga" (Embelia ribes)
• "Gorakh buti" (Aerva lanata)
• "Raj patha" (Cyclea peltata)
• "Vairi" or "salacia" (often Salacia oblonga), and
• "Lajalu" (Biophytum sensitivum)

The brand page also asserts a "unique combination of 16 herbs" and describes additional "Ayurveda" staples such as berberine source, turmeric, and jamun. However, there doesn't appear to be a full label image or a quantitative breakdown of the composition of Diabe-250.

Retail and brand pages also claim Diabe-250 "helps maintain healthy sugar levels", "improves lipid profile/reduces cholesterol", and "reduces diabetic complications", sometimes also including non-glycaemic effects such as "better sleep" and "regular bowel movement". Several pages also include the caveat that it's a "dietary nutritional supplement" and that it's "not for medicinal use". However, none of these source cite a peer-reviewed clinical trial of Diabe-250 itself.

In fact, there appear to be no peer-reviewed, product-specific clinical trials of Diabe-250 or Daiba-250 in humans; there are also no clinical trial registry records that were specific to this brand. If such a trial exists and its results were published in a peer-reviewed journal, it hasn't been cited on the sellers' or brand pages or in accessible databases.

Some ingredient classes in Diabe-250 are interesting even if they don't validate Diabe-250 as a finished product. For instance, Salacia spp., especially S. reticulata, S. oblonga, and S. chinensis have been known to be α-glucosidase inhibitors. In vitro studies and chemistry reviews have also described Salacia spp. can be potent inhibitors of maltase, sucrase, and isomaltase.

In one triple-blind, randomised crossover trial in 2023, biscuits fortified with S. reticulata extract reduced HbA1c levels by around 0.25% (2.7 mmol/mol) over three months versus the placebo, with an acceptable safety profile. In post-prandial studies involving healthy volunteers and type 2 diabetes, several randomised crossover designs had lower post-meal glucose and insulin area under the curve when Salacia extract was co-ingested along with carbohydrate.

Similarly, berberine-based neutraceuticals (such as those including Berberis aristata) have shown glycaemic improvements in the clinical literature (at large, not specific to Diabe-250) in people with type 2 diabetes. However, these effects were often reported in combination with other compounds and which researchers also indicated depended strongly on formulation and dose.

Finally, a 2022 systematic review of "Ayurvedic" medicines in people with type 2 diabetes reported heterogeneous evidence, including some promising signals, but also emphasised methodological limitations and the need for randomised controlled trials of higher quality.

Right now, if Diabe-250 works as advertised, there's no scientific proof in the public domain, especially in the form of product-specific clinical trials that define its composition, dosage, and endpoints.

In India, Ayurvedic drugs come under the Drugs & Cosmetics Rules 1945. Labelling provisions under Section 161 require details such as the manufacturer's address, batch, and manufacturing and expiry dates while practice guides also note the product license number on the label for "Ayurvedic" drugs. However, several retail pages for Diabe-250 display it as a “dietary nutritional supplement" and add that it's "not for medicinal use”, implying that it's being marketed with supplement-style claims rather than as an Ayurvedic “medicine” in the narrow regulatory sense — which runs against the claim in the CSIR post on X.com. Public pages also didn't display an AYUSH license number for Diabe-250. I haven't checked a physical pack.

A well-known study in JAMA in 2008, of "Ayurvedic" products purchased over the internet, found that around 20% of them contained lead, mercury or arsenic, and public-health advisories and case reports that have appeared since have echoed these concerns. This isn't a claim about Diabe-250 specifically but a category-level risk of "Ayurvedic" products that are available to buy online and which are compounded by the unclear composition of Diabe-250. The inconsistent naming also opens the door to counterfeit products that are also more likely to be contaminated.

Materials published by the Indian and state governments, including the Ministry of AYUSH, have framed "Ayurveda" as complementary to allopathic medicine. For example, if a person with diabetes chooses to try "Ayurvedic" support, the standard advice is to not discontinue prescribed therapy and to monitor one's glucose, especially if the individual is using α-glucosidase-like agents that alter the post-prandial response.

In sum, Diabe-250 is a multi-herb "Ayurvedic" tablet marketed by Innoveda for glycaemic support and has often been promoted with a related US patent owned by the company. However, patents are not clinical trials and patent offices don't clinically evaluate drugs described in patent applications. That information can only come from clinical trials, especially when a drug is being touted as "science-led", as the CSIR has vis-à-vis Diabe-250. But there are no published clinical trials of the product. And while there's some evidence for some of its constituents, particularly Salacia, to reduce post-prandial glucose and to effect small changes in the HbA1c levels over a few months, there's no product-specific proof.